Fostera Gold PCV MH

País: Australia

Idioma: inglés

Fuente: APVMA (Australian Pesticides and Veterinary Medicines Authority)

Ingredientes activos:

PORCINE CIRCOVIRUS TYPE 1-TYPE 2B CHIMERA INACTIVATED; PORCINE CIRCOVIRUS TYPE 1-TYPE 2A CHIMERA INACTIVATED; MYCOPLASMA HYOPNEUMONIAE - INACTIVATED ANTIGEN; THIOMERSAL

Disponible desde:

ZOETIS AUSTRALIA PTY LTD

formulario farmacéutico:

MISC. VACCINES OR ANTI SERA

Composición:

PORCINE CIRCOVIRUS TYPE 1-TYPE 2B CHIMERA INACTIVATED VACCINE-ANTIGEN/ANTIBODY Active 1.0 RP; PORCINE CIRCOVIRUS TYPE 1-TYPE 2A CHIMERA INACTIVATED Active 1.0 RP; MYCOPLASMA HYOPNEUMONIAE - INACTIVATED ANTIGEN VACCINE-GENERAL Active 1.5 RP; THIOMERSAL MERCURY Other 0.1 mg/ml

Unidades en paquete:

100 mL (50 doses); 500 mL (250 doses)

clase:

VM - Veterinary Medicine

Área terapéutica:

IMMUNOTHERAPY

Resumen del producto:

Poison schedule: 0; Withholding period: Zero (0) days Zero (0) days; Host/pest details: PIGS (BUT NOT SOWS OR BOARS): [MYCOPLASMA HYOPNEUMONIAE, PREVENTION OF PORCINE CIRCOVIRUS TYPE 2]

Estado de Autorización:

Registered

Fecha de autorización:

2023-07-01

Información para el usuario

Product Name:
APVMA Approval No:
Fostera Gold PCV MH
87927/134267
Label Name:
Fostera Gold PCV MH
Signal Headings:
FOR ANIMAL TREATMENT ONLY
Constituent
Statements:
Each dose contains inactivated Porcine Circovirus Type 1-Type 2a
Chimera (RP ≥
1.0), inactivated Porcine Circovirus Type 1-Type 2b Chimera (RP ≥
1.0) and inactivated
Mycoplasma hyopneumoniae (RP ≥ 1.5).
Also contains: ≤ 0.1 mg/ mL thiomersal (preservative)
Claims:
For active immunisation of pigs to reduce viraemia, virus load in
lymphoid tissues, the
incidence of lesions in lymphoid tissues associated with PCV2
infection and reduction in
faecal virus shedding. For active immunisation of pigs to reduce the
severity of lung lesions
caused by Mycoplasma hyopneumoniae.
Onset of immunity:
For PCV2 and Mycoplasma hyopneumoniae, 3 weeks after either a single
dose (2 mL)
vaccination or completion of the two-dose (2 x 1mL) vaccination
schedule.
Duration of immunity:
For PCV2 and Mycoplasma hyopneumoniae, 23 weeks after a single
vaccination or a two-
dose regime.
Net Contents:
100 mL (50 doses), 500 mL (250 doses)
Directions for Use:
Restraints:
Contraindications:
Precautions:
Safety studies to support the use of the product in breeding boars
have not been
conducted. No information is available on the safety and efficacy of
this vaccine when used
with other products. RLP APPROVED
Side Effects:
In a small number of pigs, a transient increase in body temperature of
up to 40.4ºC may
occur during the first 12 hours after vaccination. This usually
resolves spontaneously
within 24 hours without treatment. Immediate mild
hypersensitivity-like reactions may
occur uncommonly after vaccination, resulting in transient clinical
signs such as vomiting,
diarrhoea or depression. These clinical signs normally resolve without
treatment.
Local tissue reactions in the form of swelling at the injection site
may occur and last for up
to 2 days. The area of local reaction is usually less than 4 cm2, but
in some cases a larger
swelling may occur. Allergic reactions in pigs t